Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnoea Syndrome and Overlap Syndrome

Author(s): A. Voulgaris, K. Archontogeorgis, P. Steiropoulos, N. Papanas*

Journal Name: Current Vascular Pharmacology

Volume 19 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea syndrome (OSAS) are among the most prevalent chronic respiratory disorders. Accumulating data suggest that there is a significant burden of cardiovascular disease (CVD) in patients with COPD and OSAS, affecting negatively patients’ quality of life and survival. Overlap syndrome (OS), i.e. the co-existence of both COPD and OSAS in the same patient, has an additional impact on the cardiovascular system multiplying the risk of morbidity and mortality. The underlying mechanisms for the development of CVD in patients with either OSAS or COPD and OS are not entirely elucidated. Several mechanisms, in addition to smoking and obesity, may be implicated, including systemic inflammation, increased sympathetic activity, oxidative stress and endothelial dysfunction. Early diagnosis and proper management of these patients might reduce cardiovascular risk and improve patients' survival. In this review, we summarize the current knowledge regarding epidemiological aspects, pathophysiological mechanisms and present point-to-point specific associations between COPD, OSAS, OS and components of CVD, namely, pulmonary hypertension, coronary artery disease, peripheral arterial disease and stroke.

Keywords: Cardiovascular disease, coronary artery disease, chronic obstructive pulmonary disease, obstructive sleep apnoea syndrome, overlap syndrome, peripheral arterial disease, pulmonary hypertension, stroke.

[1]
Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2019.https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf2019
[2]
Rabe KF, Hurst JR, Suissa S. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev 2018; 27(149): 150.
[http://dx.doi.org/10.1183/16000617.0057-2018] [PMID: 30282634]
[3]
Konecny T, Somers K, Orban M, et al. Interactions between COPD and outcomes after percutaneous coronary intervention. Chest 2010; 138(3): 621-7.
[http://dx.doi.org/10.1378/chest.10-0300] [PMID: 20382719]
[4]
Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65(11): 956-62.
[http://dx.doi.org/10.1136/thx.2009.128082] [PMID: 20871122]
[5]
Reed RM, Eberlein M, Girgis RE, et al. Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. Am J Med 2012; 125: 1228. e13-22
[http://dx.doi.org/10.1016/j.amjmed.2012.05.018]
[6]
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015; 3(8): 631-9.
[http://dx.doi.org/10.1016/S2213-2600(15)00241-6] [PMID: 26208998]
[7]
Morgan AD, Rothnie KJ, Bhaskaran K, Smeeth L, Quint JK. Chronic obstructive pulmonary disease and the risk of 12 cardiovascular diseases: a population-based study using UK primary care data. Thorax 2018; 73(9): 877-9.
[http://dx.doi.org/10.1136/thoraxjnl-2017-210865] [PMID: 29438071]
[8]
Maclay JD, MacNee W. Cardiovascular disease in COPD: mechanisms. Chest 2013; 143(3): 798-807.
[http://dx.doi.org/10.1378/chest.12-0938] [PMID: 23460157]
[9]
Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011; 6: 413-21.
[http://dx.doi.org/10.2147/COPD.S10770] [PMID: 21857781]
[10]
Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 2009; 179(1): 35-40.
[http://dx.doi.org/10.1164/rccm.200804-560OC] [PMID: 18931335]
[11]
Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59(7): 574-80.
[http://dx.doi.org/10.1136/thx.2003.019588] [PMID: 15223864]
[12]
Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185(10): 1065-72.
[http://dx.doi.org/10.1164/rccm.201110-1792OC] [PMID: 22427534]
[13]
Moro L, Pedone C, Scarlata S, Malafarina V, Fimognari F, Antonelli-Incalzi R. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology 2008; 59(3): 357-64.
[http://dx.doi.org/10.1177/0003319707306141] [PMID: 18388072]
[14]
Palange P, Testa U, Huertas A, et al. Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur Respir J 2006; 27(3): 529-41.
[http://dx.doi.org/10.1183/09031936.06.00120604] [PMID: 16507853]
[15]
MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2(1): 50-60.
[http://dx.doi.org/10.1513/pats.200411-056SF] [PMID: 16113469]
[16]
Münzel T, Camici GG, Maack C, Bonetti NR, Fuster V, Kovacic JC. Impact of oxidative stress on the heart and vasculature: Part 2 of a 3-Part Series. J Am Coll Cardiol 2017; 70(2): 212-29.
[http://dx.doi.org/10.1016/j.jacc.2017.05.035] [PMID: 28683969]
[17]
Lomas DA. Does protease-antiprotease imbalance explain chronic obstructive pulmonary disease? Ann Am Thorac Soc 2016; 13(Suppl. 2): S130-7.
[PMID: 27115947]
[18]
Hua Y, Nair S. Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications. Biochim Biophys Acta 2015; 1852(2): 195-208.
[http://dx.doi.org/10.1016/j.bbadis.2014.04.032] [PMID: 24815358]
[19]
Ito I, Nagai S, Handa T, et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005; 172(11): 1378-82.
[http://dx.doi.org/10.1164/rccm.200506-953OC] [PMID: 16126934]
[20]
Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94(6): 2493-503.
[http://dx.doi.org/10.1172/JCI117619] [PMID: 7989608]
[21]
Fimognari FL, Scarlata S, Conte ME, Incalzi RA. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3(1): 89-96.
[PMID: 18488431]
[22]
Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103(13): 1718-20.
[http://dx.doi.org/10.1161/01.CIR.103.13.1718] [PMID: 11282900]
[23]
Vaidyula VR, Criner GJ, Grabianowski C, Rao AK. Circulating tissue factor procoagulant activity is elevated in stable moderate to severe chronic obstructive pulmonary disease. Thromb Res 2009; 124(3): 259-61.
[http://dx.doi.org/10.1016/j.thromres.2008.12.030] [PMID: 19162305]
[24]
Undas A, Kaczmarek P, Sladek K, et al. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment. Thromb Haemost 2009; 102(6): 1176-82.
[PMID: 19967149]
[25]
Vonk-Noordegraaf A, Marcus JT, Holverda S, Roseboom B, Postmus PE. Early changes of cardiac structure and function in COPD patients with mild hypoxemia. Chest 2005; 127(6): 1898-903.
[http://dx.doi.org/10.1378/chest.127.6.1898] [PMID: 15947300]
[26]
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and Treatment of pulmonary hypertension of the european society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J 2016; 37(1): 67-119.
[http://dx.doi.org/10.1093/eurheartj/ehv317] [PMID: 26320113]
[27]
Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008; 32(5): 1371-85.
[http://dx.doi.org/10.1183/09031936.00015608] [PMID: 18978137]
[28]
Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2(1): 8-11.
[http://dx.doi.org/10.1513/pats.200404-032MS] [PMID: 16113462]
[29]
Engström G, Wollmer P, Hedblad B, Juul-Möller S, Valind S, Janzon L. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from “men born in 1914,” Malmö, Sweden. Circulation 2001; 103(25): 3086-91.
[http://dx.doi.org/10.1161/01.CIR.103.25.3086] [PMID: 11425773]
[30]
Lahousse L, Niemeijer MN, van den Berg ME, et al. Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. Eur Heart J 2015; 36(27): 1754-61.
[http://dx.doi.org/10.1093/eurheartj/ehv121] [PMID: 25920404]
[31]
Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med 2002; 166(3): 333-9.
[http://dx.doi.org/10.1164/rccm.2110093] [PMID: 12153966]
[32]
Brekke PH, Omland T, Smith P, Søyseth V. Underdiagnosis of myocardial infarction in COPD - Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med 2008; 102(9): 1243-7.
[http://dx.doi.org/10.1016/j.rmed.2008.04.010] [PMID: 18595681]
[33]
Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107(11): 1514-9.
[http://dx.doi.org/10.1161/01.CIR.0000056767.69054.B3] [PMID: 12654609]
[34]
Søyseth V, Bhatnagar R, Holmedahl NH, et al. Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart 2013; 99(2): 122-6.
[http://dx.doi.org/10.1136/heartjnl-2012-302685] [PMID: 23024006]
[35]
Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128(4): 2099-107.
[http://dx.doi.org/10.1378/chest.128.4.2099] [PMID: 16236861]
[36]
Rasmussen T, Køber L, Pedersen JH, et al. Relationship between chronic obstructive pulmonary disease and subclinical coronary artery disease in long-term smokers. Eur Heart J Cardiovasc Imaging 2013; 14(12): 1159-66.
[http://dx.doi.org/10.1093/ehjci/jet057] [PMID: 23639550]
[37]
Cazzola M, Calzetta L, Matera MG, Muscoli S, Rogliani P, Romeo F. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med 2015; 109(8): 1019-25.
[http://dx.doi.org/10.1016/j.rmed.2015.05.021] [PMID: 26111914]
[38]
Morley RL, Sharma A, Horsch AD, Hinchliffe RJ. Peripheral artery disease. BMJ 2018; 360: j5842.
[http://dx.doi.org/10.1136/bmj.j5842] [PMID: 29419394]
[39]
Houben-Wilke S, Jörres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pul-monary disease in the copd and systemic consequences-comorbidities network study. Am J Respir Crit Care Med 2017; 195(2): 189-97.
[http://dx.doi.org/10.1164/rccm.201602-0354OC] [PMID: 27532739]
[40]
Pecci R, De La Fuente Aguado J, Sanjurjo Rivo AB, Sanchez Conde P, Corbacho Abelaira M. Peripheral arterial disease in patients with chronic obstructive pulmonary disease. Int Angiol 2012; 31(5): 444-53.
[PMID: 22990507]
[41]
Pizarro C, Linnhoff F, van Essen F, et al. Lower extremity and carotid artery disease in COPD. ERJ Open Res 2016; 2(4): 00037-2016.
[http://dx.doi.org/10.1183/23120541.00037-2016] [PMID: 28053972]
[42]
Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Cazzola M, Siafakas N. Chronic obstructive pulmonary disease and stroke. COPD 2018; 15(4): 405-13.
[http://dx.doi.org/10.1080/15412555.2018.1464551] [PMID: 29746193]
[43]
Portegies ML, Lahousse L, Joos GF, et al. Chronic obstructive pulmonary disease and the risk of stroke. The Rotterdam Study. Am J Respir Crit Care Med 2016; 193(3): 251-8.
[http://dx.doi.org/10.1164/rccm.201505-0962OC] [PMID: 26414484]
[44]
Windsor C, Herrett E, Smeeth L, Quint JK. No association between exacerbation frequency and stroke in patients with COPD. Int J Chron Obstruct Pulmon Dis 2016; 11: 217-25.
[PMID: 26893553]
[45]
Söderholm M, Inghammar M, Hedblad B, Egesten A, Engström G. Incidence of stroke and stroke subtypes in chronic obstructive pul-monary disease. Eur J Epidemiol 2016; 31(2): 159-68.
[http://dx.doi.org/10.1007/s10654-015-0113-7] [PMID: 26711630]
[46]
Gulsvik AK, Gulsvik A, Skovlund E, et al. The association between lung function and fatal stroke in a community followed for 4 decades. J Epidemiol Community Health 2012; 66(11): 1030-6.
[http://dx.doi.org/10.1136/jech-2011-200312] [PMID: 22493479]
[47]
Truelsen T, Prescott E, Lange P, Schnohr P, Boysen G. Lung function and risk of fatal and non-fatal stroke. The Copenhagen city heart study. Int J Epidemiol 2001; 30(1): 145-51.
[http://dx.doi.org/10.1093/ije/30.1.145] [PMID: 11171876]
[48]
Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet 2014; 383(9918): 736-47.
[http://dx.doi.org/10.1016/S0140-6736(13)60734-5] [PMID: 23910433]
[49]
Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013; 177(9): 1006-14.
[http://dx.doi.org/10.1093/aje/kws342] [PMID: 23589584]
[50]
Al Lawati NM, Patel SR, Ayas NT. Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration. Prog Cardiovasc Dis 2009; 51(4): 285-93.
[http://dx.doi.org/10.1016/j.pcad.2008.08.001] [PMID: 19110130]
[51]
Tietjens JR, Claman D, Kezirian EJ, et al. Obstructive sleep apnea in cardiovascular disease: a review of the literature and proposed multidisciplinary clinical management strategy. J Am Heart Assoc 2019; 8(1)e010440
[http://dx.doi.org/10.1161/JAHA.118.010440] [PMID: 30590966]
[52]
Durgan DJ, Bryan RM Jr. Cerebrovascular consequences of obstructive sleep apnea. J Am Heart Assoc 2012; 1(4)e000091
[http://dx.doi.org/10.1161/JAHA.111.000091] [PMID: 23130152]
[53]
Voulgaris A, Archontogeorgis K, Nena E, et al. Serum levels of NGAL and cystatin C as markers of early kidney dysfunction in patients with obstructive sleep apnea syndrome. Sleep Breath 2019; 23(1): 161-9.
[http://dx.doi.org/10.1007/s11325-018-1677-8] [PMID: 29946947]
[54]
Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290(14): 1906-14.
[http://dx.doi.org/10.1001/jama.290.14.1906] [PMID: 14532320]
[55]
Wang X, Zhang Y, Dong Z, Fan J, Nie S, Wei Y. Effect of continuous positive airway pressure on long-term cardiovascular outcomes in patients with coronary artery disease and obstructive sleep apnea: a systematic review and meta-analysis. Respir Res 2018; 19(1): 61.
[http://dx.doi.org/10.1186/s12931-018-0761-8] [PMID: 29636058]
[56]
McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016; 375(10): 919-31.
[http://dx.doi.org/10.1056/NEJMoa1606599] [PMID: 27571048]
[57]
Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31(8): 1071-8.
[PMID: 18714778]
[58]
Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365(9464): 1046-53.
[http://dx.doi.org/10.1016/S0140-6736(05)71141-7] [PMID: 15781100]
[59]
Campos-Rodriguez F, Martinez-Garcia MA, de la Cruz-Moron I, Almeida-Gonzalez C, Catalan-Serra P, Montserrat JM. Cardiovascular mortality in women with obstructive sleep apnea with or without continuous positive airway pressure treatment: a cohort study. Ann Intern Med 2012; 156(2): 115-22.
[http://dx.doi.org/10.7326/0003-4819-156-2-201201170-00006] [PMID: 22250142]
[60]
Martínez-García MA, Campos-Rodríguez F, Catalán-Serra P, et al. Cardiovascular mortality in obstructive sleep apnea in the elderly: role of long-term continuous positive airway pressure treatment: a prospective observational study. Am J Respir Crit Care Med 2012; 186(9): 909-16.
[http://dx.doi.org/10.1164/rccm.201203-0448OC] [PMID: 22983957]
[61]
Anker SD, von Haehling S, Germany R. Sleep-disordered breathing and cardiovascular disease. Indian Heart J 2016; 68(Suppl. 1): S69-76.
[http://dx.doi.org/10.1016/j.ihj.2015.11.018] [PMID: 27056657]
[62]
Somers VK, White DP, Amin R, et al. sleep apnea and cardiovascular disease: an american heart association/american college of cardiology foundation scientific statement from the american heart association council for high blood pressure research professional education committee, council on clinical cardiology, stroke council, and council on cardiovascular nursing. In collaboration with the national heart, lung, and blood institute national center on sleep disorders research (national institutes of health). Circulation 2008; 118(10): 1080-111.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.189420] [PMID: 18725495]
[63]
Shiomi T, Guilleminault C, Stoohs R, Schnittger I. Leftward shift of the interventricular septum and pulsus paradoxus in obstructive sleep apnea syndrome. Chest 1991; 100(4): 894-902.
[http://dx.doi.org/10.1378/chest.100.4.894] [PMID: 1914603]
[64]
Jellinek H, Krenn H, Oczenski W, Veit F, Schwarz S, Fitzgerald RD. Influence of positive airway pressure on the pressure gradient for venous return in humans. J Appl Physiol 2000; 88(3): 926-32.
[http://dx.doi.org/10.1152/jappl.2000.88.3.926] [PMID: 10710387]
[65]
Brinker JA, Weiss JL, Lappé DL, et al. Leftward septal displacement during right ventricular loading in man. Circulation 1980; 61(3): 626-33.
[http://dx.doi.org/10.1161/01.CIR.61.3.626] [PMID: 7353253]
[66]
Linz D, Schotten U, Neuberger HR, Böhm M, Wirth K. Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm 2011; 8(9): 1436-43.
[http://dx.doi.org/10.1016/j.hrthm.2011.03.053] [PMID: 21457790]
[67]
Bradley TD, Hall MJ, Ando S, Floras JS. Hemodynamic effects of simulated obstructive apneas in humans with and without heart failure. Chest 2001; 119(6): 1827-35.
[http://dx.doi.org/10.1378/chest.119.6.1827] [PMID: 11399711]
[68]
Tolle FA, Judy WV, Yu PL, Markand ON. Reduced stroke volume related to pleural pressure in obstructive sleep apnea. J Appl Physiol 1983; 55(6): 1718-24.
[http://dx.doi.org/10.1152/jappl.1983.55.6.1718] [PMID: 6662762]
[69]
Kasai T, Bradley TD. Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications. J Am Coll Cardiol 2011; 57(2): 119-27.
[http://dx.doi.org/10.1016/j.jacc.2010.08.627] [PMID: 21211682]
[70]
Golia E, Limongelli G, Natale F, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep 2014; 16(9): 435.
[http://dx.doi.org/10.1007/s11883-014-0435-z] [PMID: 25037581]
[71]
Ryan S, Taylor CT, McNicholas WT. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in ob-structive sleep apnoea syndrome? Thorax 2009; 64(7): 631-6.
[PMID: 19561283]
[72]
Archontogeorgis K, Nena E, Papanas N, Steiropoulos P. Biomarkers to improve diagnosis and monitoring of obstructive sleep apnea syndrome: current status and future perspectives. Pulm Med 2014; 2014930535
[http://dx.doi.org/10.1155/2014/930535] [PMID: 25538852]
[73]
Badran M, Ayas N, Laher I. Cardiovascular complications of sleep apnea: role of oxidative stress. Oxid Med Cell Longev 2014; 2014985258
[http://dx.doi.org/10.1155/2014/985258] [PMID: 24734153]
[74]
Eisele HJ, Markart P, Schulz R. Obstructive sleep apnea, oxidative stress, and cardiovascular disease: evidence from human studies. Oxid Med Cell Longev 2015; 2015608438
[http://dx.doi.org/10.1155/2015/608438] [PMID: 26167241]
[75]
Barceló A, Barbé F, de la Peña M, et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006; 27(4): 756-60.
[http://dx.doi.org/10.1183/09031936.06.00067605] [PMID: 16585082]
[76]
Faure P, Tamisier R, Baguet JP, et al. Impairment of serum albumin antioxidant properties in obstructive sleep apnoea syndrome. Eur Respir J 2008; 31(5): 1046-53.
[http://dx.doi.org/10.1183/09031936.00062707] [PMID: 18256067]
[77]
Liak C, Fitzpatrick M. Coagulability in obstructive sleep apnea. Can Respir J 2011; 18(6): 338-48.
[http://dx.doi.org/10.1155/2011/924629] [PMID: 22187690]
[78]
Steiropoulos P, Voulgaris A, Papanas N. Cardiovascular disease and obstructive sleep apnea: an underappreciated role for increased platelet activity? Expert Opin Pharmacother 2018; 19(10): 1043-4.
[http://dx.doi.org/10.1080/14656566.2018.1491242] [PMID: 29924660]
[79]
Oga T, Chin K, Tabuchi A, et al. Effects of obstructive sleep apnea with intermittent hypoxia on platelet aggregability. J Atheroscler Thromb 2009; 16(6): 862-9.
[http://dx.doi.org/10.5551/jat.2188] [PMID: 20032579]
[80]
Nena E, Papanas N, Steiropoulos P, et al. Mean platelet volume and platelet distribution Width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity? Platelets 2012; 23(6): 447-54.
[http://dx.doi.org/10.3109/09537104.2011.632031] [PMID: 22070405]
[81]
Bisogni V, Pengo MF, Maiolino G, Rossi GP. The sympathetic nervous system and catecholamines metabolism in obstructive sleep apnoea. J Thorac Dis 2016; 8(2): 243-54.
[PMID: 26904265]
[82]
Zakrzewski M, Zakrzewska E, Kiciński P, et al. Evaluation of fibrinolytic inhibitors: alpha-2-antiplasmin and plasminogen activator inhibitor 1 in patients with obstructive sleep apnoea. PLoS One 2016; 11(11)e0166725
[http://dx.doi.org/10.1371/journal.pone.0166725] [PMID: 27861608]
[83]
Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23(2): 168-75.
[http://dx.doi.org/10.1161/01.ATV.0000051384.43104.FC] [PMID: 12588755]
[84]
Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100(2): 158-73.
[http://dx.doi.org/10.1161/01.RES.0000255691.76142.4a] [PMID: 17272818]
[85]
Feng J, Zhang D, Chen B. Endothelial mechanisms of endothelial dysfunction in patients with obstructive sleep apnea. Sleep Breath 2012; 16(2): 283-94.
[http://dx.doi.org/10.1007/s11325-011-0519-8] [PMID: 21479903]
[86]
Atkeson A, Jelic S. Mechanisms of endothelial dysfunction in obstructive sleep apnea. Vasc Health Risk Manag 2008; 4(6): 1327-35.
[http://dx.doi.org/10.2147/VHRM.S4078] [PMID: 19337546]
[87]
Tsara V, Amfilochiou A, Papagrigorakis MJ, Georgopoulos D, Liolios E. Guidelines for diagnosis and treatment of sleep-related breathing disorders in adults and children. Definition and classification of sleep related breathing disorders in adults: different types and indications for sleep studies (Part 1). Hippokratia 2009; 13(3): 187-91.
[PMID: 19918312]
[88]
Somers VK, Mark AL, Zavala DC, Abboud FM. Influence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol 1989; 67(5): 2095-100.
[http://dx.doi.org/10.1152/jappl.1989.67.5.2095] [PMID: 2513315]
[89]
Brooks D, Horner RL, Kozar LF, Render-Teixeira CL, Phillipson EA. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Invest 1997; 99(1): 106-9.
[http://dx.doi.org/10.1172/JCI119120] [PMID: 9011563]
[90]
Narkiewicz K, Somers VK. Cardiovascular variability characteristics in obstructive sleep apnea. Auton Neurosci 2001; 90(1-2): 89-94.
[http://dx.doi.org/10.1016/S1566-0702(01)00272-7] [PMID: 11485297]
[91]
Hillebrand S, Gast KB, de Mutsert R, et al. Heart rate variability and first cardiovascular event in populations without known cardio-vascular disease: meta-analysis and dose-response meta-regression. Europace 2013; 15(5): 742-9.
[http://dx.doi.org/10.1093/europace/eus341] [PMID: 23370966]
[92]
Parati G, Ochoa JE, Salvi P, Lombardi C, Bilo G. Prognostic value of blood pressure variability and average blood pressure levels in patients with hypertension and diabetes. Diabetes Care 2013; 36(Suppl. 2): S312-24.
[http://dx.doi.org/10.2337/dcS13-2043] [PMID: 23882065]
[93]
Kholdani C, Fares WH, Mohsenin V. Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology. Pulm Circ 2015; 5(2): 220-7.
[http://dx.doi.org/10.1086/679995] [PMID: 26064448]
[94]
Wong HS, Williams AJ, Mok Y. The relationship between pulmonary hypertension and obstructive sleep apnea. Curr Opin Pulm Med 2017; 23(6): 517-21.
[http://dx.doi.org/10.1097/MCP.0000000000000421] [PMID: 28786883]
[95]
Chaouat A, Weitzenblum E, Krieger J, Oswald M, Kessler R. Pulmonary hemodynamics in the obstructive sleep apnea syndrome. Results in 220 consecutive patients. Chest 1996; 109(2): 380-6.
[http://dx.doi.org/10.1378/chest.109.2.380] [PMID: 8620709]
[96]
Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009; 104(9): 1300-6.
[http://dx.doi.org/10.1016/j.amjcard.2009.06.048] [PMID: 19840581]
[97]
Sajkov D, Wang T, Saunders NA, Bune AJ, Mcevoy RD. Continuous positive airway pressure treatment improves pulmonary hemodynamics in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2002; 165(2): 152-8.
[http://dx.doi.org/10.1164/ajrccm.165.2.2010092] [PMID: 11790646]
[98]
Arias MA, García-Río F, Alonso-Fernández A, Martínez I, Villamor J. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 2006; 27(9): 1106-13.
[http://dx.doi.org/10.1093/eurheartj/ehi807] [PMID: 16497687]
[99]
Atwood CW Jr, McCrory D, Garcia JG, Abman SH, Ahearn GS. Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. Chest 2004; 126(1)(Suppl.): 72S-7S.
[http://dx.doi.org/10.1378/chest.126.1_suppl.72S] [PMID: 15249496]
[100]
Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58(5): 811-7.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.179788] [PMID: 21968750]
[101]
Hou H, Zhao Y, Yu W, et al. Association of obstructive sleep apnea with hypertension: A systematic review and meta-analysis. J Glob Health 2018; 8(1)010405
[http://dx.doi.org/10.7189/jogh.08.010405] [PMID: 29497502]
[102]
Iturriaga R, Oyarce MP, Dias ACR. Role of carotid body in intermittent hypoxia-related hypertension. Curr Hypertens Rep 2017; 19(5): 38.
[http://dx.doi.org/10.1007/s11906-017-0735-0] [PMID: 28451849]
[103]
Jouett NP, Watenpaugh DE, Dunlap ME, Smith ML. Interactive effects of hypoxia, hypercapnia and lung volume on sympathetic nerve activity in humans. Exp Physiol 2015; 100(9): 1018-29.
[http://dx.doi.org/10.1113/EP085092] [PMID: 26132990]
[104]
Jin ZN, Wei YX. Meta-analysis of effects of obstructive sleep apnea on the renin-angiotensin-aldosterone system. J Geriatr Cardiol 2016; 13(4): 333-43.
[PMID: 27403143]
[105]
Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342(19): 1378-84.
[http://dx.doi.org/10.1056/NEJM200005113421901] [PMID: 10805822]
[106]
Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320(7233): 479-82.
[http://dx.doi.org/10.1136/bmj.320.7233.479] [PMID: 10678860]
[107]
Fletcher EC, DeBehnke RD, Lovoi MS, Gorin AB. Undiagnosed sleep apnea in patients with essential hypertension. Ann Intern Med 1985; 103(2): 190-5.
[http://dx.doi.org/10.7326/0003-4819-103-2-190] [PMID: 4014900]
[108]
Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contributing factors to the production of essential hyper-tension? Curr Hypertens Rep 2001; 3(3): 209-15.
[http://dx.doi.org/10.1007/s11906-001-0040-8] [PMID: 11353571]
[109]
Williams AJ, Houston D, Finberg S, Lam C, Kinney JL, Santiago S. Sleep apnea syndrome and essential hypertension. Am J Cardiol 1985; 55(8): 1019-22.
[http://dx.doi.org/10.1016/0002-9149(85)90738-6] [PMID: 3984861]
[110]
Marin JM, Agusti A, Villar I, et al. Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 2012; 307(20): 2169-76.
[http://dx.doi.org/10.1001/jama.2012.3418] [PMID: 22618924]
[111]
Martynowicz H, Skomro R, Gac P, et al. The influence of hypertension on daytime sleepiness in obstructive sleep apnea. J Am Soc Hypertens 2017; 11: 295-302.
[112]
Barbé F, Mayoralas LR, Duran J, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness. A randomized, controlled trial. Ann Intern Med 2001; 134(11): 1015-23.
[http://dx.doi.org/10.7326/0003-4819-134-11-200106050-00007] [PMID: 11388814]
[113]
Hedner J, Bengtsson-Boström K, Peker Y, Grote L, Råstam L, Lindblad U. Hypertension prevalence in obstructive sleep apnoea and sex: a population-based case-control study. Eur Respir J 2006; 27(3): 564-70.
[http://dx.doi.org/10.1183/09031936.06.00042105] [PMID: 16507857]
[114]
Martínez-García MA, Capote F, Campos-Rodríguez F, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA 2013; 310(22): 2407-15.
[http://dx.doi.org/10.1001/jama.2013.281250] [PMID: 24327037]
[115]
Logan AG, Tkacova R, Perlikowski SM, et al. Refractory hypertension and sleep apnoea: effect of CPAP on blood pressure and baro-reflex. Eur Respir J 2003; 21(2): 241-7.
[http://dx.doi.org/10.1183/09031936.03.00035402] [PMID: 12608436]
[116]
Barbé F, Durán-Cantolla J, Capote F, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181(7): 718-26.
[http://dx.doi.org/10.1164/rccm.200901-0050OC] [PMID: 20007932]
[117]
Lüthje L, Andreas S. Obstructive sleep apnea and coronary artery disease. Sleep Med Rev 2008; 12(1): 19-31.
[http://dx.doi.org/10.1016/j.smrv.2007.08.002] [PMID: 17936040]
[118]
De Torres-Alba F, Gemma D, Armada-Romero E, Rey-Blas JR, López-de-Sá E, López-Sendon JL. Obstructive sleep apnea and coronary artery disease: from pathophysiology to clinical implications. Pulm Med 2013; 2013768064
[http://dx.doi.org/10.1155/2013/768064] [PMID: 23691310]
[119]
Morra S, Roubille F. Obstructive sleep apnoea: from respiratory events to coronary microvascular dysfunction. Acta Cardiol 2018; 73(4): 319-24.
[http://dx.doi.org/10.1080/00015385.2017.1384183] [PMID: 28990847]
[120]
Shpilsky D, Erqou S, Patel SR, et al. Association of obstructive sleep apnea with microvascular endothelial dysfunction and subclinical coronary artery disease in a community-based population. Vasc Med 2018; 23(4): 331-9.
[http://dx.doi.org/10.1177/1358863X18755003] [PMID: 29537350]
[121]
Zhang T, Zhang C, Chen RX, Shao B, Liu GA. Correlation between coronary artery lesion quantitative score and OSAHS and relative risk factors. Eur Rev Med Pharmacol Sci 2018; 22(5): 1415-20.
[PMID: 29565502]
[122]
Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010; 122(4): 352-60.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.901801] [PMID: 20625114]
[123]
Wang X, Fan JY, Zhang Y, Nie SP, Wei YX. Association of obstructive sleep apnea with cardiovascular outcomes after percutaneous coronary intervention: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97(17)e0621
[http://dx.doi.org/10.1097/MD.0000000000010621] [PMID: 29703065]
[124]
Buchner S, Eglseer M, Debl K, et al. Sleep disordered breathing and enlargement of the right heart after myocardial infarction. Eur Respir J 2015; 45(3): 680-90.
[http://dx.doi.org/10.1183/09031936.00057014] [PMID: 25359347]
[125]
Buchner S, Satzl A, Debl K, et al. Impact of sleep-disordered breathing on myocardial salvage and infarct size in patients with acute myocardial infarction. Eur Heart J 2014; 35(3): 192-9.
[http://dx.doi.org/10.1093/eurheartj/eht450] [PMID: 24164862]
[126]
Linz D, Woehrle H, Bitter T, et al. The importance of sleep-disordered breathing in cardiovascular disease. Clin Res Cardiol 2015; 104(9): 705-18.
[http://dx.doi.org/10.1007/s00392-015-0859-7] [PMID: 25903111]
[127]
Schahab N, Sudan S, Schaefer C, et al. Sleep apnoea is common in severe peripheral arterial disease. PLoS One 2017; 12(7)e0181733
[http://dx.doi.org/10.1371/journal.pone.0181733] [PMID: 28759652]
[128]
Pizarro C, Schaefer C, Kimeu I, et al. Underdiagnosis of obstructive sleep apnoea in peripheral arterial disease. Respiration 2015; 89: 214-20.
[http://dx.doi.org/10.1159/000371355] [PMID: 25720463]
[129]
Schaefer CA, Adam L, Weisser-Thomas J, et al. High prevalence of peripheral arterial disease in patients with obstructive sleep apnoea. Clin Res Cardiol 2015; 104(9): 719-26.
[http://dx.doi.org/10.1007/s00392-015-0834-3] [PMID: 25725776]
[130]
Shah N, Allison M, Teng Y, et al. Sleep apnea is independently associated with peripheral arterial disease in the Hispanic community health study/study of Latinos. Arterioscler Thromb Vasc Biol 2015; 35(3): 710-5.
[http://dx.doi.org/10.1161/ATVBAHA.114.304625] [PMID: 25657310]
[131]
Nagayoshi M, Lutsey PL, Benkeser D, et al. Association of sleep apnea and sleep duration with peripheral artery disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2016; 251: 467-75.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.06.040] [PMID: 27423537]
[132]
Wardly DE. Intracranial hypertension associated with obstructive sleep apnea: a discussion of potential etiologic factors. Med Hypotheses 2014; 83(6): 792-7.
[http://dx.doi.org/10.1016/j.mehy.2014.10.011] [PMID: 25456788]
[133]
Bålfors EM, Franklin KA. Impairment of cerebral perfusion during obstructive sleep apneas. Am J Respir Crit Care Med 1994; 150(6 Pt 1): 1587-91.
[http://dx.doi.org/10.1164/ajrccm.150.6.7952619] [PMID: 7952619]
[134]
Franklin KA. Cerebral haemodynamics in obstructive sleep apnoea and Cheyne-Stokes respiration. Sleep Med Rev 2002; 6(6): 429-41.
[http://dx.doi.org/10.1053/smrv.2001.0206] [PMID: 12505476]
[135]
Urbano F, Roux F, Schindler J, Mohsenin V. Impaired cerebral autoregulation in obstructive sleep apnea. J Appl Physiol 2008; 105(6): 1852-7.
[http://dx.doi.org/10.1152/japplphysiol.90900.2008] [PMID: 18927265]
[136]
Nasr N, Traon AP, Czosnyka M, Tiberge M, Schmidt E, Larrue V. Cerebral autoregulation in patients with obstructive sleep apnea syndrome during wakefulness. Eur J Neurol 2009; 16(3): 386-91.
[http://dx.doi.org/10.1111/j.1468-1331.2008.02505.x] [PMID: 19175381]
[137]
Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med 2010; 6(2): 131-7.
[http://dx.doi.org/10.5664/jcsm.27760] [PMID: 20411688]
[138]
Das AM, Khan M. Obstructive sleep apnea and stroke. Expert Rev Cardiovasc Ther 2012; 10(4): 525-35.
[http://dx.doi.org/10.1586/erc.12.25] [PMID: 22458584]
[139]
Dong R, Dong Z, Liu H, Shi F, Du J. prevalence, risk factors, outcomes, and treatment of obstructive sleep apnea in patients with cerebrovascular disease: A systematic review. J Stroke Cerebrovasc Dis 2018; 27(6): 1471-80.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2017.12.048] [PMID: 29555400]
[140]
Sharma S, Culebras A. Sleep apnoea and stroke. Stroke Vasc Neurol 2016; 1(4): 185-91.
[http://dx.doi.org/10.1136/svn-2016-000038] [PMID: 28959482]
[141]
Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353(19): 2034-41.
[http://dx.doi.org/10.1056/NEJMoa043104] [PMID: 16282178]
[142]
Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea and 20-year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the Busselton Health Study cohort. J Clin Sleep Med 2014; 10(4): 355-62.
[http://dx.doi.org/10.5664/jcsm.3600] [PMID: 24733978]
[143]
Arzt M, Young T, Finn L, Skatrud JB, Bradley TD. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 2005; 172(11): 1447-51.
[http://dx.doi.org/10.1164/rccm.200505-702OC] [PMID: 16141444]
[144]
Hsu CY, Vennelle M, Li HY, Engleman HM, Dennis MS, Douglas NJ. Sleep-disordered breathing after stroke: a randomised controlled trial of continuous positive airway pressure. J Neurol Neurosurg Psychiatry 2006; 77(10): 1143-9.
[http://dx.doi.org/10.1136/jnnp.2005.086686] [PMID: 16772358]
[145]
Hui DS, Choy DK, Wong LK, et al. Prevalence of sleep-disordered breathing and continuous positive airway pressure compliance: results in chinese patients with first-ever ischemic stroke. Chest 2002; 122(3): 852-60.
[http://dx.doi.org/10.1378/chest.122.3.852] [PMID: 12226023]
[146]
Abuzaid AS, Al Ashry HS, Elbadawi A, et al. Meta-Analysis of cardiovascular outcomes with continuous positive airway pressure therapy in patients with obstructive sleep apnea. Am J Cardiol 2017; 120(4): 693-9.
[http://dx.doi.org/10.1016/j.amjcard.2017.05.042] [PMID: 28651851]
[147]
Flenley DC. Sleep in chronic obstructive lung disease. Clin Chest Med 1985; 6(4): 651-61.
[PMID: 2935359]
[148]
McNicholas WT. Comorbid obstructive sleep apnoea and chronic obstructive pulmonary disease and the risk of cardiovascular disease. J Thorac Dis 2018; 10(Suppl. 34): S4253-61.
[http://dx.doi.org/10.21037/jtd.2018.10.117] [PMID: 30687541]
[149]
Ioachimescu OC, Teodorescu M. Integrating the overlap of obstructive lung disease and obstructive sleep apnoea: OLDOSA syndrome. Respirology 2013; 18(3): 421-31.
[http://dx.doi.org/10.1111/resp.12062] [PMID: 23368952]
[150]
Shawon MS, Perret JL, Senaratna CV, Lodge C, Hamilton GS, Dharmage SC. Current evidence on prevalence and clinical outcomes of co-morbid obstructive sleep apnea and chronic obstructive pulmonary disease: A systematic review. Sleep Med Rev 2017; 32: 58-68.
[http://dx.doi.org/10.1016/j.smrv.2016.02.007] [PMID: 28169105]
[151]
Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182(3): 325-31.
[http://dx.doi.org/10.1164/rccm.200912-1869OC] [PMID: 20378728]
[152]
Du W, Liu J, Zhou J, Ye D, OuYang Y, Deng Q. Obstructive sleep apnea, COPD, the overlap syndrome, and mortality: results from the 2005-2008 National Health and Nutrition Examination Survey. Int J Chron Obstruct Pulmon Dis 2018; 13: 665-74.
[http://dx.doi.org/10.2147/COPD.S148735] [PMID: 29520134]
[153]
Lacedonia D, Carpagnano GE, Patricelli G, et al. Prevalence of comorbidities in patients with obstructive sleep apnea syndrome, overlap syndrome and obesity hypoventilation syndrome. Clin Respir J 2018; 12(5): 1905-11.
[http://dx.doi.org/10.1111/crj.12754] [PMID: 29227046]
[154]
Papachatzakis I, Velentza L, Zarogoulidis P, Kallianos A, Trakada G. Comorbidities in coexisting chronic obstructive pulmonary disease and obstructive sleep apnea - overlap syndrome. Eur Rev Med Pharmacol Sci 2018; 22(13): 4325-31.
[PMID: 30024626]
[155]
Hang LW, Hsu JY, Chang CJ, et al. Predictive factors warrant screening for obstructive sleep apnea in COPD: a Taiwan National Survey. Int J Chron Obstruct Pulmon Dis 2016; 11: 665-73.
[PMID: 27099484]
[156]
Kendzerska T, Leung RS, Aaron SD, Ayas N, Sandoz JS, Gershon AS. Cardiovascular outcomes and all-cause mortality in patients with obstructive sleep apnea and chronic obstructive pulmonary disease (overlap syndrome). Ann Am Thorac Soc 2019; 16(1): 71-81.
[http://dx.doi.org/10.1513/AnnalsATS.201802-136OC] [PMID: 30372124]
[157]
Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med 2006; 173(8): 910-6.
[http://dx.doi.org/10.1164/rccm.200509-1442OC] [PMID: 16424443]
[158]
Ganga HV, Nair SU, Puppala VK, Miller WL. Risk of new-onset atrial fibrillation in elderly patients with the overlap syndrome: a retrospective cohort study. J Geriatr Cardiol 2013; 10(2): 129-34.
[PMID: 23888171]
[159]
Hawryłkiewicz I, Sliwiński P, Górecka D, Pływaczewski R, Zieliński J. Pulmonary haemodynamics in patients with OSAS or an overlap syndrome. Monaldi Arch Chest Dis 2004; 61(3): 148-52.
[http://dx.doi.org/10.4081/monaldi.2004.693] [PMID: 15679007]
[160]
Steveling EH, Clarenbach CF, Miedinger D, et al. Predictors of the overlap syndrome and its association with comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2014; 88(6): 451-7.
[http://dx.doi.org/10.1159/000368615] [PMID: 25472034]
[161]
Ryan S, McNicholas WT. Intermittent hypoxia and activation of inflammatory molecular pathways in OSAS. Arch Physiol Biochem 2008; 114(4): 261-6.
[http://dx.doi.org/10.1080/13813450802307337] [PMID: 18946786]
[162]
Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112(17): 2660-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.556746] [PMID: 16246965]
[163]
Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161(4 Pt 1): 1179-84.
[http://dx.doi.org/10.1164/ajrccm.161.4.9903022] [PMID: 10764309]
[164]
Taranto-Montemurro L, Messineo L, Perger E, et al. Cardiac sympathetic hyperactivity in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. COPD 2016; 13(6): 706-11.
[http://dx.doi.org/10.1080/15412555.2016.1199668] [PMID: 27383268]
[165]
Archontogeorgis K, Voulgaris A, Papanas N, et al. Mean platelet volume and platelet distribution width in patients with obstructive sleep apnea syndrome and concurrent chronic obstructive pulmonary disease. Clin Appl Thromb Hemost 2018; 24(8): 1216-22.
[http://dx.doi.org/10.1177/1076029618788178] [PMID: 30016881]
[166]
Lavie L. Obstructive sleep apnoea syndrome--an oxidative stress disorder. Sleep Med Rev 2003; 7(1): 35-51.
[http://dx.doi.org/10.1053/smrv.2002.0261] [PMID: 12586529]
[167]
MacNee W. Oxidants/antioxidants and COPD. Chest 2000; 117(5)(Suppl. 1): 303-17.
[http://dx.doi.org/10.1378/chest.117.5_suppl_1.303S-a] [PMID: 10843965]
[168]
Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284(23): 3015-21.
[http://dx.doi.org/10.1001/jama.284.23.3015] [PMID: 11122588]
[169]
Kim V, Goel N, Gangar J, et al. Risk factors for venous thromboembolism in chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis (Miami) 2014; 1(2): 239-49.
[http://dx.doi.org/10.15326/jcopdf.1.2.2014.0133] [PMID: 25844397]
[170]
Malerba M, Nardin M, Radaeli A, Montuschi P, Carpagnano GE, Clini E. The potential role of endothelial dysfunction and platelet activation in the development of thrombotic risk in COPD patients. Expert Rev Hematol 2017; 10(9): 821-32.
[http://dx.doi.org/10.1080/17474086.2017.1353416] [PMID: 28693343]
[171]
Bradley TD, Rutherford R, Grossman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985; 131(6): 835-9.
[PMID: 4003933]
[172]
Weitzenblum E, Krieger J, Apprill M, et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 1988; 138(2): 345-9.
[http://dx.doi.org/10.1164/ajrccm/138.2.345] [PMID: 3143285]
[173]
Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med 1995; 151(1): 82-6.
[http://dx.doi.org/10.1164/ajrccm.151.1.7812577] [PMID: 7812577]
[174]
Sharma B, Neilan TG, Kwong RY, et al. Evaluation of right ventricular remodeling using cardiac magnetic resonance imaging in co-existent chronic obstructive pulmonary disease and obstructive sleep apnea. COPD 2013; 10(1): 4-10.
[http://dx.doi.org/10.3109/15412555.2012.719050] [PMID: 23272670]
[175]
Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55(13): 1318-27.
[http://dx.doi.org/10.1016/j.jacc.2009.10.061] [PMID: 20338492]
[176]
Shiina K, Tomiyama H, Takata Y, et al. Overlap syndrome: additive effects of COPD on the cardiovascular damages in patients with OSA. Respir Med 2012; 106(9): 1335-41.
[http://dx.doi.org/10.1016/j.rmed.2012.05.006] [PMID: 22705293]
[177]
Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 2010; 90(2): 513-57.
[http://dx.doi.org/10.1152/physrev.00007.2009] [PMID: 20393193]
[178]
Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 2016; 354: i4482.
[http://dx.doi.org/10.1136/bmj.i4482] [PMID: 27599725]
[179]
Matsumoto T, Murase K, Tachikawa R, et al. Microalbuminuria in patients with obstructive sleep apnea-chronic obstructive pulmonary disease overlap syndrome. Ann Am Thorac Soc 2016; 13(6): 917-25.
[http://dx.doi.org/10.1513/AnnalsATS.201510-655OC] [PMID: 26966922]
[180]
Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8(1): 148-56.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03584.x] [PMID: 19691485]
[181]
Gaul DS, Stein S, Matter CM. Neutrophils in cardiovascular disease. Eur Heart J 2017; 38(22): 1702-4.
[http://dx.doi.org/10.1093/eurheartj/ehx244] [PMID: 30052884]
[182]
Macrea M, Campbell S, Martin T, Oursler KA. The peripheral neutrophils in subjects with COPD-OSA overlap syndrome and severe comorbidities: A feasible inflammatory biomarker? Adv Clin Exp Med 2018; 27(12): 1677-82.
[http://dx.doi.org/10.17219/acem/75904] [PMID: 30085419]
[183]
Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006; 28(6): 1245-57.
[http://dx.doi.org/10.1183/09031936.00133805] [PMID: 17138679]
[184]
Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128(4): 2640-6.
[http://dx.doi.org/10.1378/chest.128.4.2640] [PMID: 16236937]
[185]
Leitao Filho FS, Sin DD. COPD and cardiovascular diseases: now is the time for action! Thorax 2018; 73(9): 799-800.
[http://dx.doi.org/10.1136/thoraxjnl-2018-211553] [PMID: 29622696]
[186]
Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med 2018; 198(1): 51-7.
[http://dx.doi.org/10.1164/rccm.201711-2239OC] [PMID: 29442524]
[187]
Mermigkis C, Kopanakis A, Foldvary-Schaefer N, et al. Health-related quality of life in patients with obstructive sleep apnoea and chronic obstructive pulmonary disease (overlap syndrome). Int J Clin Pract 2007; 61(2): 207-11.
[http://dx.doi.org/10.1111/j.1742-1241.2006.01213.x] [PMID: 17263708]
[188]
Stanchina ML, Welicky LM, Donat W, Lee D, Corrao W, Malhotra A. Impact of CPAP use and age on mortality in patients with combined COPD and obstructive sleep apnea: the overlap syndrome. J Clin Sleep Med 2013; 9(8): 767-72.
[http://dx.doi.org/10.5664/jcsm.2916] [PMID: 23946706]
[189]
Wang TY, Lo YL, Lee KY, et al. Nocturnal CPAP improves walking capacity in COPD patients with obstructive sleep apnoea. Respir Res 2013; 14: 66.
[http://dx.doi.org/10.1186/1465-9921-14-66] [PMID: 23782492]
[190]
Archontogeorgis K, Voulgaris A, Nena E, et al. Cardiovascular risk assessment in a cohort of newly diagnosed patients with obstructive sleep apnea syndrome. Cardiol Res Pract 2018; 20186572785
[http://dx.doi.org/10.1155/2018/6572785] [PMID: 29707392]
[191]
Voulgaris A, Nena E, Steiropoulos P. Comment on: Comorbidities in coexisting chronic obstructive pulmonary disease and obstructive sleep apnea - overlap syndrome. Eur Rev Med Pharmacol Sci 2018; 22(19): 6171-2.
[PMID: 30338831]
[192]
Katsiki N, Mikhailidis DP, Banach M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol Sin 2018; 39(7): 1176-88.
[http://dx.doi.org/10.1038/aps.2018.40] [PMID: 29877321]
[193]
Katsiki N, Mikhailidis DP, Papanas N. Depression in cardiac and non-cardiac vascular diseases: Current evidence and future perspectives. Int J Cardiol 2018; 271: 21-2.
[http://dx.doi.org/10.1016/j.ijcard.2018.07.055] [PMID: 30031624]
[194]
Katsiki N, Mikhailidis DP. Lipids: a personal view of the past decade. Hormones (Athens) 2018; 17(4): 461-78.
[http://dx.doi.org/10.1007/s42000-018-0058-9] [PMID: 30229482]
[195]
Mazidi M, Kengne AP, Katsiki N, Mikhailidis DP, Banach M. Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults. Br J Nutr 2018; 120(11): 1272-8.
[http://dx.doi.org/10.1017/S0007114518002581] [PMID: 30378506]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2021
Published on: 17 March, 2020
Page: [285 - 300]
Pages: 16
DOI: 10.2174/1570161118666200318103553
Price: $65

Article Metrics

PDF: 39
HTML: 3